CAMP4 Therapeutics (NASDAQ:CAMP) Raised to Strong-Buy at Chardan Capital

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by stock analysts at Chardan Capital to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities research analysts have also weighed in on CAMP. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective for the company. Weiss Ratings lowered CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Finally, Leerink Partners lifted their target price on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a research report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.25.

CAMP4 Therapeutics Stock Up 8.2%

Shares of NASDAQ CAMP opened at $4.34 on Wednesday. CAMP4 Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $7.75. The business has a 50 day moving average price of $4.37 and a two-hundred day moving average price of $4.68. The firm has a market cap of $225.38 million, a PE ratio of -1.84 and a beta of 0.08.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The business had revenue of $1.29 million for the quarter. On average, analysts anticipate that CAMP4 Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of CAMP4 Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its stake in CAMP4 Therapeutics by 35.9% during the 4th quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider’s stock valued at $38,807,000 after acquiring an additional 1,666,666 shares in the last quarter. Vivo Capital LLC raised its stake in CAMP4 Therapeutics by 8.3% during the 4th quarter. Vivo Capital LLC now owns 4,246,568 shares of the Wireless communications provider’s stock valued at $26,031,000 after acquiring an additional 325,000 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in CAMP4 Therapeutics during the 4th quarter valued at $14,938,000. Adage Capital Partners GP L.L.C. raised its stake in CAMP4 Therapeutics by 11.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,181,679 shares of the Wireless communications provider’s stock valued at $13,374,000 after acquiring an additional 220,895 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new position in shares of CAMP4 Therapeutics during the 1st quarter valued at $1,497,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.